Since co‑founding Addex in 2002, Mr. Dyer has played a pivotal role in building the Addex Group, raising significant capital, including Addex IPO, Nadaq listing, Neurosterix spin-out and negotiating licensing agreements with pharmaceutical industry partners. Prior to founding Addex, he spent 10 years with Price Waterhouse, or PW & PricewaterhouseCoopers, or PwC in the UK and Switzerland as part of the audit and business advisory group. Mr. Dyer has extensive experience in finance, corporate development, business operations and the building of start‑up companies. He is a UK Chartered Accountant and holds a BSc (Hons) in Biochemistry and Pharmacology from the University of Southampton, UK. Mr Dyer is also CEO and a board member of Neurosterix, an allosteric modulator drug discovery and development company created by Addex and Perceptive advisors based on the Addex allosteric modulator drug discovery technology platform and preclinical.